Linzess, a medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), has multiple patents protecting its composition and use [1].
When does the main Linzess patent expire?
The primary patent covering the composition of matter for Linzess is expected to expire around December 2027 [2].
Are there other patents that could extend Linzess exclusivity?
Yes, there are additional patents related to Linzess, including those for methods of use and manufacturing processes. These patents can influence the drug's market exclusivity and potential generic entry dates. DrugPatentWatch.com tracks these various patents and their expiration timelines [1][3].
What is the significance of patent expiration for Linzess?
Patent expiration allows for the potential introduction of generic versions of Linzess. This typically leads to lower drug prices and increased market competition [4].
How does patent expiration affect Linzess availability?
Once key patents expire, and if no other market exclusivities are in place, generic manufacturers can apply for approval to sell their versions of Linzess. This process often involves regulatory review and potential legal challenges from the brand-name manufacturer [4].
Who makes Linzess?
Linzess is manufactured by Ironwood Pharmaceuticals and AbbVie [1].